2. Search Result
Search Result
Results for "

placebo

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156654
    Ibuzatrelvir
    1 Publications Verification

    PF-07817883

    		 SARS-CoV Virus Protease Infection
    Ibuzatrelvir (PF-07817883), a second-generation, orally bioavailable, is SARS-CoV-2 main protease (M pro and 3CL pro) inhibitor with improved metabolic stability. Ibuzatrelvir has demonstrated pan-human coronavirus antiviral activity and off-target selectivity profile in vitro and in preclinical animal studies. Ibuzatrelvir is well tolerated with a safety profile similar to placebo and prevents viral infection and transmission. Ibuzatrelvir can be used to inhibit COVID-19 .
    Ibuzatrelvir
  • HY-172242
    Verducatib

    		Cathepsin Dipeptidyl Peptidase Inflammation/Immunology
    Verducatib (BI 1291583) is an orally active inhibitor of cathepsin C (also known as DPP1). Verducatib restores the protease-inhibitor balance by inhibiting the activation of neutrophil serine proteases, thereby alleviating pulmonary inflammation and regulating infection responses. Verducatib significantly reduces the risk (including severe exacerbations) and frequency of acute exacerbations in bronchiectasis (BE). Verducatib also improves lung function and quality of life, and shortens the duration of antibiotic use. The overall incidence of adverse events of Verducatib is comparable to that of placebo, with only slightly more mild-to-moderate cutaneous adverse events observed in the high-dose group, demonstrating promising clinical application potential .
    Verducatib
  • HY-163529
    HN0037

    		HSV Cytochrome P450 Infection
    HN0037 is a selective, orally active Helicase-primase inhibitor. HN0037 is mainly metabolized by CYP3A4. HN0037 inhibits HSV replication by targeting the viral helicase-primase complex, which consists of three proteins encoded by UL5 (helicase), UL52 (primase), and UL8 (scaffold protein that promotes primer synthesis) .
    HN0037
  • HY-117287A
    Deucravacitinib hydrochloride

    BMS-986165 hydrochloride

    		 Interleukin Related JAK IFNAR Inflammation/Immunology
    Deucravacitinib hydrochloride (BMS-986165 hydrochloride) is a highly selective all-site inhibitor with potent inhibitory activity against TYK2. Deucravacitinib hydrochloride can effectively block IL-12, IL-23 and type I interferon signaling. Deucravacitinib hydrochloride demonstrates significant efficacy in preclinical models of inflammatory bowel disease. Deucravacitinib hydrochloride demonstrated superiority over placebo and apremilast on multiple efficacy endpoints in moderate to severe plaque psoriasis. Deucravacitinib hydrochloride was well tolerated in inhibition .
    Deucravacitinib hydrochloride
  • HY-149155
    o-Cymen-5-ol

    		Bacterial Infection
    o-Cymen-5-ol is a broad-spectrum antimicrobial agent with direct antimicrobial activity. o-Cymen-5-ol showed effective minimum inhibitory concentrations (MICs) against a variety of bacteria and fungi, such as Streptococcus mutans and Candida albicans. The combination of o-Cymen-5-ol and zinc showed synergistic effects, enhancing the inhibitory effect against oral pathogens. o-Cymen-5-ol was able to inhibit the glycolysis process and co-enhanced this effect with zinc. o-Cymen-5-ol showed a stronger antibacterial effect in toothpaste than placebo .
    o-Cymen-5-ol
  • HY-14742
    Faxeladol

    		Opioid Receptor Others
    Faxeladol is a compound with analgesic activity that reduced mean pain intensity compared with placebo in a suppression trial for painful polyneuropathy with a favorable safety profile.
    Faxeladol
  • HY-125316
    AMG-151

    ARRY-403

    		 Endogenous Metabolite Metabolic Disease
    AMG-151 (ARRY-403) is a glucokinase agonist with fasting plasma glucose (FPG) lowering activity. AMG-151 showed a significant linear dose-response trend compared with placebo in a randomized, placebo-controlled Phase IIa study. The use of AMG-151 was associated with a higher incidence of hypoglycemia and hypertriglyceridemia. AMG-151 may serve as a potential compound for the inhibition of type 1 diabetes .
    AMG-151
  • HY-169115A
    (Rac)-PD0299685

    		Calcium Channel Inflammation/Immunology
    (Rac)-PD0299685 is a Ca(2+) channel α2δ ligand that was investigated for relieving interstitial cystitis pain in a randomized, double-blind, placebo-controlled phase IIa study. (Rac)-PD0299685 demonstrated a clinically significant reduction in daily worst pain severity scores at the 60 mg dose compared to placebo. (Rac)-PD0299685 is also a potent voltage-dependent calcium channel inhibitor for the study of retina-related diseases.
    (Rac)-PD0299685
  • HY-101080
    3'-Fluorobenzylspiperone maleate

    		Dopamine Receptor Neurological Disease
    3'-Fluorobenzylspiperone maleate is a ligand for dopamine D2 receptors with activity in improving behavioral disorders. 3'-Fluorobenzylspiperone maleate showed better inhibitory effects than placebo, especially in reducing behavioral disorders .
    3'-Fluorobenzylspiperone maleate
  • HY-124356
    Alcaftadine carboxylic acid

    		Histamine Receptor Inflammation/Immunology
    Alcaftadine carboxylic acid is a broad-spectrum antihistamine compound with high affinity for histamine H1 and H2 receptors and low affinity for H4 receptors. Alcaftadine carboxylic acid has also demonstrated effects on modulating immune cell recruitment and stabilizing mast cells. Alcaftadine carboxylic acid is more effective than placebo in preventing ocular itching associated with allergic conjunctivitis and is at least as effective as olopatadine 0.01% .
    Alcaftadine carboxylic acid
  • HY-124356AS
    Alcaftadine carboxylic acid-d3 sodium

    		Isotope-Labeled Compounds Histamine Receptor Inflammation/Immunology
    Alcaftadine carboxylic acid-d3 (sodium) is deuterium labeled Alcaftadine carboxylic acid. Alcaftadine carboxylic acid is a broad-spectrum antihistamine compound with high affinity for histamine H1 and H2 receptors and low affinity for H4 receptors. Alcaftadine carboxylic acid has also demonstrated effects on modulating immune cell recruitment and stabilizing mast cells. Alcaftadine carboxylic acid is more effective than placebo in preventing ocular itching associated with allergic conjunctivitis and is at least as effective as olopatadine 0.01% .
    Alcaftadine carboxylic acid-d3 sodium
  • HY-118756
    Anirolac

    RS37326

    		 Endogenous Metabolite Inflammation/Immunology
    Anirolac (RS37326) is a nonsteroidal anti-inflammatory agent with analgesic activity. Anirolac showed analgesic efficacy comparable to that of naproxen in suppressing moderate or severe postpartum uterine pain. Anirolac induced significantly higher analgesia scores than placebo within 6 hours, especially at the 100 mg dose. Anirolac effectively relieved pain and showed a stronger analgesic effect than placebo in every assessment .
    Anirolac
  • HY-W008613A
    Amitriptyline pamoate

    		Endogenous Metabolite Metabolic Disease Cancer
    Amitriptyline pamoate is a common oral anticholinergic. Amitriptyline pamoate has anticholinergic properties. Amitriptyline pamoate can be used to quantify anticholinergic adverse reactions in patients taking amitriptyline and placebo .
    Amitriptyline pamoate
  • HY-123154
    PDE10A-IN-4

    		Phosphodiesterase (PDE) Others
    PDE10A-IN-4 (compound 38) is a compound used to inhibit schizophrenia. As a PDE10A inhibitor, it is less effective than placebo in inhibiting acute schizophrenia and does not show antipsychotic effect.
    PDE10A-IN-4
  • HY-129482
    Detoxin D1

    		Others Others
    Detoxin D1 is a compound with antihistamine activity and a new type of H1 antagonist. In the suppression of seasonal allergic rhinitis, a daily dose of 10-30 mg has an equivalent and highly effective inhibitory effect compared with placebo and has good safety.
    Detoxin D1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: